Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy
and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found
such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific
anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47%
declare a complete disease after five years. The aim of this study is to assess in this
particular population the preventive effect of an anti-platelet treatment.